Lonza to invest in SA manufacturing JV
This article was originally published in Scrip
Executive Summary
Lonza is in negotiations with the South African government to establish a $200 million (R1.6 billion) joint-venture manufacturing plant to produce antiretroviral medicines for use within the country.